Both MEK and AKT inhibition resulted in dose-dependent DIPG cell death with IC50s in the nM range (Fig. 7k, l, Supplementary Fig. S7k, l) supporting these as important therapeutic targets for H3K27M-driven cancer. The gene discussed is AKT1; the disease is cancer.